BioNTech
BNTX
Market cap $28.9B

121.55 USD

-1.13

0.92%

At close Oct 7, 4:00 PM EDT

After hours

121.56

+0.01

0.01%

1 day

-0.92%

5 days

1.37%

1 month

20.91%

3 months

51.01%

6 months

36.10%

Year to date

8.19%

1 year

11.20%

5 years

753.58%

About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

Employees: 6,133

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 16 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

20% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]

6% more call options, than puts

Call options by funds: $145M | Put options by funds: $137M

0% less funds holding

Funds holding: 283 [Q1] → 282 (-1) [Q2]

0.44% less ownership

Funds ownership: 17.67% [Q1] → 17.24% (-0.44%) [Q2]

3% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 37

14% less repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 98

15% less capital invested

Capital invested by funds: $3.88B [Q1] → $3.29B (-$587M) [Q2]

See Fund Rankings

Research analyst outlook

16 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$85

30%

downside

Avg. target

$122

1%

upside

High target

$150

23%

upside

16 analyst ratings

11 positive

69%

4 neutral

25%

1 negative

6%

HSBC Yifeng Liu 100% 1-year accuracy 1 / 1 met price target	12%upside $136	Buy Maintained	7 Oct 2024
HC Wainwright & Co. Robert Burns 37% 1-year accuracy 57 / 156 met price target	23%upside $150	Buy Maintained	7 Oct 2024
Morgan Stanley Terence Flynn 68% 1-year accuracy 15 / 22 met price target	19%upside $145	Overweight Upgraded	24 Sept 2024
Deutsche Bank Emmanuel Papadakis 100% 1-year accuracy 3 / 3 met price target	23%upside $150	Buy Maintained	19 Sept 2024
UBS Eliana Merle 33% 1-year accuracy 4 / 12 met price target	8%upside $131	Neutral Maintained	18 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about BNTX published over the past 30 days

BioNTech (BNTX) Presents at Innovation Series: AI Day

BioNTech SE (NASDAQ:BNTX ) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer, BioNTech Ryan Richardson - Chief Strategy Officer, BioNTech Nacef Labidi - Head of Infrastructure, InstaDeep Alex Laterre - Head of Research, InstaDeep Alex Graves - Research Scientist, InstaDeep Bora Guloglu - Research Scientist, InstaDeep Julia Gimbernat - Product Manager, InstaDeep Arnu Pretorius - Research Scientist, InstaDeep Youssef Ben Dhieb - Senior ML Engineer, InstaDeep Thomas Pierrot - Research Scientist, InstaDeep Maren Lang - Senior Director, Bioinformatics R&D, BioNTech Marie Lopez - Research Engineer Team Lead, InstaDeep Daniel Rothenberg - Associate Director, Proteomics, BioNTech Michael Rooney - Director, Computational Biology, BioNTech Nicolas Lopez Carranza - Head of BioAI, InstaDeep Hippolyte Jacomet - Research Engineer, InstaDeep Sven Coutandin - Director, Global R&D Automation, BioNTech David Drakard - Senior Research Engineer, InstaDeep Michael Dahms - Director, Digitization R&D Labs, BioNTech Conference Call Participants Sam Fazeli - Bloomberg Intelligence Harry - Time Magazine Ian Johnston - Financial Times Unidentified Speaker - Karim Beguir Hi everyone. Welcome to AI Day.

BioNTech (BNTX) Presents at Innovation Series: AI Day

BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day

LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence (“AI”) subsidiary InstaDeep Ltd . (“InstaDeep”), today presents an overview of its AI approach during an edition of the Company's Innovation Series, AI Day.

BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day

Zacks Investment Research

PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab

The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.

PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission wil.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European Commission in July 2024 Doses will be ready to ship to applicable European Union member states as soon as possible upon European Commission authorization NEW YORK and MAINZ, GERMANY, SEPTEMBER 20, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission (“EC”) will review the CHMP's recommendation and is expected to make a final decision soon.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

BioNTech Is More Than a Covid-19 Stock. It's Having a Great September.

Recently BioNTech has been boosted a wave of enthusiasm over another company's cancer drug, which has turned the biopharma industry upside down.

BioNTech Is More Than a Covid-19 Stock. It's Having a Great September.

Investors Business Daily

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery

BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024

MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day, an edition of BioNTech's “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Tuesday, October 1st, 2024 in London, United Kingdom. The event will provide an overview of BioNTech's and InstaDeep's AI strategy and capabilities, and the application of AI in BioNTech's pipeline and internal processes.

BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024

CNBC Television

Trade It or Fade It: The week's big biotech moves

Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.

Trade It or Fade It: The week's big biotech moves

Zacks Investment Research

BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?

See News Rankings

Charts implemented using Lightweight Charts™